Guggenheim Upgrades BeiGene, Ltd. (BGNE) to Buy
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
SVB Leerink Upgrades BeiGene, Ltd. (BGNE) to Outperform
October 12, 2022 4:20 PM EDTSVB Leerink analyst Andrew Berens upgraded BeiGene, Ltd. (NASDAQ: BGNE) from Market Perform to Outperform with a price target of $200.00 (from $177.00).
For an analyst ratings summary and ratings history on BeiGene, Ltd. click here. For more ratings news on BeiGene, Ltd. click here.
Shares of BeiGene, Ltd. closed at $125.51 yesterday.
... MoreBeiGene (BGNE) Announces Positive Topline Results from Final PFS Analysis of BRUKINSA Compared to IMBRUVICA in Phase 3 CLL Trial
October 12, 2022 7:04 AM EDTBeiGene (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global biotechnology company focused on developing innovative and affordable oncology medicines to improve treatment outcomes and access for patients worldwide, today announced that BRUKINSA® (zanubrutinib) achieved superior Progression-Free Survival (PFS) versus IMBRUVICA® (ibrutinib) in a final analysis of the Phase 3 ALPINE trial, as assessed by an independent review committee (IRC) and investigator. BRUKINSA was generally well tolerated; safety findings at the final PFS analysis were consistent with prior reports.
This positive result adds to the growing body of evidence... More
